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Abstract
E26 transformation-specific (ETS) transcription factors are known to be involved in gene aberrations in various
malignancies including prostate cancer; however, their role in melanoma oncogenesis has yet to be fully explored.
We have completed a comprehensive fluorescence in situ hybridization (FISH)–based screen for all 27 members of
the ETS transcription factor family on two melanoma tissue microarrays, representing 223 melanomas, 10 nevi,
and 5 normal skin tissues. None of the melanoma cases demonstrated ETS fusions; however, 6 of 114 (5.3%)
melanomas were amplified for ETV1 using a break-apart FISH probe. For the six positive cases, locus-controlled
FISH probes revealed that two of six cases were amplified for the ETV1 region, whereas four cases showed copy
gains of the entire chromosome 7. The remaining 26 ETS family members showed no chromosomal aberrations by
FISH. Quantitative polymerase chain reaction showed an average 3.4-fold (P value = .00218) increased expression
of ETV1 in melanomas, including the FISH ETV1–amplified cases, when compared to other malignancies (prostate,
breast, and bladder carcinomas). These data suggest that a subset of melanomas overexpresses ETV1 and ampli-
fication of ETV1 may be one mechanism for achieving high gene expression.
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Introduction
In a world being driven by precision medicine [1,2], there is an
impetus toward finding gene aberrations in deadly tumors of various
types that might elucidate the biology of such high-grade malig-
nancies or identify potential therapeutic targets. Although melanomas
account for less than 5% of all skin cancers, they are responsible for the
majority of skin cancer–related deaths [3]. Furthermore, the incidence
of melanomas is increasing worldwide in white populations [4]. Early
detection of melanomas allows surgical excision with high cure rates.
However, once melanomas disseminate outside of their primary cuta-
neous location, they are usually refractory to current therapeutic modal-
ities and, in fact, carry a dismal prognosis. The most recent 5-year
relative survival rates from the National Cancer Institute’s Surveillance
Epidemiology and End Results review were 98.2% for localized dis-
ease, 62.4% for cancers spread to regional lymph nodes or beyond
the primary site, and 15.1% for melanomas with distant metastases
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[5]. Thus, there is an intense need for identification of genetic aber-
rations in melanomas that can detail the pathobiology of this tumor
or be informative for identifying rational therapies currently available
or in clinical trials.
E26 transformation-specific (ETS) transcription factors consist of
27 members, many of which have been shown to play a role in cancer
initiation and progression [6]. Gene fusions involving ETS family
members are implicated in numerous malignancies including Ewing
sarcoma, infantile fibrosarcoma, breast cancer, myelodysplastic syn-
dromes, acute lymphoblastic leukemia, and acute myeloid leukemia.
Recurrent gene fusions have traditionally been thought to play only
a minor role in solid tumors, largely because of technical limitations
of cytogenetics. In the past few years, however, an increasing number
of recurrent gene fusions have been recognized in epithelial cancers
[7–10]. Our group has recently discovered and elucidated the involve-
ment of four members of the ETS family transcription factors, ERG,
ETV1, ETV4, and ETV5, in recurrent gene fusion events in a major-
ity of clinically localized and castration-resistant metastatic prostate
cancers [7,11–14]. In the prostate, gene fusions result in aberrant
overexpression of the ETS transcription factor in prostate epithelial
cells and confer a neoplastic phenotype [8,15].
A recent study has identified ETV1 amplification in 13% of primary
and 18% of metastatic melanomas [16]. Interestingly, telomerase re-
verse transcriptase (TERT) promoter mutations have also been identi-
fied within melanomas that generate de novo consensus binding motifs
for the ETS transcription factors [1]. However, no definitive studies
that have done a comprehensive investigation of aberrations involving
ETS family members in melanomas exist. Because ETS transcription
factors are key proto-oncogenes playing an important role in many dif-
ferent cancers, we decided to use a comprehensive fluorescence in situ
Figure 1. Schematic for comprehensive ETS FISH screen in melanoma and follow-up analysis of amplified cases. (A) Break-apart FISH
probe design for each member of the 27 ETS family. The ETS gene is shown as a teal-colored box with direction of transcription indi-
cated by the overlying arrow. 5′ and 3′ BACs are indicated with their corresponding probe color. (B) Schematic for possible outcomes of
FISH-based screening using the split probe strategy outlined in A. Tightly co-localizing red and green signals produce yellow fluores-
cence; the cell nucleus is highlighted in blue using 4′6-diamidino-2-phenylindole. Translocation (split) is indicated by separation in space
of the 5′ and 3′ probe pairs. Amplification is detected by greater than two copies of the probed locus. A deletion is indicated by loss of
one 5′ or 3′ signal. In our experiments, we discovered six melanoma cases that were amplified for ETV1 by the above scheme. (C) To
assess whether the six positive cases were amplified specifically for the ETV1 locus, we rehybridized the cases with an ETV1-specific
probe (green) and a commercially available centromeric probe, CEP7 (orange).
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hybridization (FISH) screen to determine if any chromosomal aberra-
tions involving the ETS family exist in melanomas.
Materials and Methods
Study Population, Clinical Data, and
Tissue Microarray Construction
Two melanoma tissue microarrays (TMAs) were constructed as
previously described [13]. Briefly, melanoma patients were identified
by searching the University of Michigan pathology archives. Slides
were reviewed for diagnosis, staging parameters, and adequate tumor
volume by the pathologists involved in this study (R.M., D.S.L.K.,
and D.R.F.). The first TMA consists of 118 unique tissues spotted in
triplicates and includes 107 melanomas (87 primary and 20 meta-
static) and 11 controls (5 normal skin, 3 benign nevi, and 3 dysplastic
nevi). The second TMA consists of 120 unique tissues spotted in
triplicates and includes 116 metastatic melanomas and 4 benign nevi.
This study was approved by the University of Michigan Medical
School’s Institutional Review Board.
FISH Screening Strategy
A previously validated FISH-based split probe strategy was used to
screen the 27 ETS family members on the two melanoma TMAs
[17]. Bacterial artificial chromosomes (BACs) were obtained from
the BACPAC Resource Center (Oakland, CA), and probes were
prepared as described [13,15,17]. The integrity and correct localiza-
tion of all probes were verified by hybridization to metaphase spreads
of normal peripheral lymphocytes. Slides were examined using an
ImagingZ1 microscope (Carl Zeiss, Oberkochen, Germany). FISH
signals were scored manually (100× oil immersion) in morphologi-
cally intact and non-overlapping nuclei by a pathologist with exten-
sive experience in FISH evaluation (R.M.); a minimum of 50 cancer
cells from each site was recorded. Cancer sites with very weak or no
signals were recorded as insufficient hybridization.
A schematic representing our FISH-based screening strategy is
shown in Figure 1. ETS gene–specific split probes flanking the gene
of interest (100–1000 kb) were used to screen the melanoma TMAs.
Cases positive for amplification by the initial split probe screen were
rehybridized with an ETV1 locus–specific probe (RP11-124L22)
and a commercially available centromeric (locus-controlled) FISH
probe to chromosome 7, Vysis CEP7 (Abbott Park, IL).
Quantitative Real-Time Reverse Transcription–Polymerase
Chain Reaction
Quantitative polymerase chain reaction (Q-PCR) was carried out
according to standard protocols as previously described [7,15,17].
Briefly, total RNA was extracted from formalin-fixed paraffin-embedded
melanoma specimens. ETV1 (forward: aacagccctttaaattcagctatgga and
reverse: ggagggcctcattcccacttg) and glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH) oligonucleotide primers were synthesized by
Figure 2. ETV1 locus–controlled FISH. (A) Benign nevus control with normal copy number of ETV1/chromosome 7. (B) Melanoma cells
with normal copy number of ETV1/chromosome 7. (C) Primary melanoma with ETV1-specific amplification; ETV1 locus–specific probe
(green) shows greater than two copies per nucleus, whereas chromosome 7 centromeric probe CEP7 (orange) demonstrates the normal
two copies. (D) Melanoma aneuploid for chromosome 7. Balanced increase in both ETV1 and CEP7.
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Integrated DNA Technologies (Coralville, IA). All samples were nor-
malized to the housekeeping gene GAPDH and calibrated to Clontech
normal liver (Mountain View, CA) ETV1 expression levels.
Results and Discussion
We screened for the presence of chromosomal aberrations among all
the 27 ETS family genes using FISH split probe hybridizations on
our two melanoma TMAs; cases positive for amplifications were
rehybridized with a locus-controlled FISH probe (see Figure 1 for
schematic). Initial FISH screening using split probes revealed 6 cases
amplified for ETV1 of 114 evaluable cases (5.3%). Remaining 26
ETS loci were negative for chromosomal aberrations (Figure 1B)
on our melanoma TMAs by the FISH approach described above.
Tissue sections from the six amplification-positive melanoma cases
identified by the initial split-apart FISH approach were rehybridized
with an ETV1-specific probe along with a probe specific to the centro-
mere of chromosome 7 (CEP7) as detailed in Figure 1C . Two cases, a
primary melanoma and a metastatic melanoma, were found to be
amplified specifically for the ETV1 locus (representative image of
primary melanoma case, Figure 2C ). The remaining four cases were
amplified for entire chromosome 7 (representative image, Figure 2D).
All other cases on the two melanoma TMAs, including normal skin,
nevi (representative image, Figure 2A), and non-amplified melanomas
(representative image, Figure 2B), demonstrated the normal two copies
of CEP7 and ETV1.
We next queried the Oncomine database (version Q4, November
2012) for ETS family gene expression in the melanoma samples. To
date, 10 studies have reported a total of 24,524 data points (1010 nevi
and 23,514 melanoma) from 404 specimens (20 nevi and 384 mela-
noma) characterized by Affymetrix array platforms (U133A, U133A 2.0,
and 133 Plus 2.0). ETV2 gene was not represented in the data sets
and was excluded from this analysis. Outlier expression analysis of the
26 ETS family genes revealed a differential expression of select mem-
bers in melanoma compared to the benign nevi samples (Figure 3).
Specifically, ETV1 gene showed outlier expression in approximately
12% of the samples at 95% confidence interval (Figure 3). Similarly,
ETV5 (7.4%), ELF1 (11.9%), EHF (9%), and ETS2 (12%) genes also
showed outlier expression revealing broad ETS family dysregulation in
melanoma samples. To assess whether chromosome 7 amplification
and/or ETV1-specific amplification in melanomas correlated with in-
creased expression levels of ETV1, we performed real-time Q-PCR.
ETV1-specific primers spanning the exon 5/6 junction were used
in all Q-PCR experiments (Figure 4A). Relative quantification was
Figure 3. ETS family gene outlier expression analysis in melanoma samples. Melanoma gene expression data sets available in the
Oncomine database were queried for 26 ETS family outlier expression. Box plot represents expression of ETS family members in benign
nevi (B), n = 20, and melanoma (M) specimens, n = 384. ETV1 gene (red arrow) showed outlier expression in approximately 12% of the
samples at 95% confidence interval; however, the median expression was not significantly different between nevi and melanoma.
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performed using the ΔΔCT method. The Q-PCR data are summarized
using box plots; a central rectangle indicates the first to third quartiles
with a horizontal line within the box corresponding to the median, the
whiskers indicate the minimum and maximum, and individual tumor
samples are represented by dots in the background (Figure 4, B and C).
Figure 4B, from left to right, shows box plots of 6 amplified mela-
nomas (two ETV1 locus specific amplified cases are highlighted by
clear dots and the four melanomas with chromosome 7 amplifica-
tions are indicated by black dots), 15 non-amplified melanomas,
9 nevi (7 benign nevi indicated by black dots and 2 dysplastic nevi
highlighted by clear dots), 17 breast cancer cases, 3 prostate cancers,
and 3 bladder cancers. Figure 4C shows data from Figure 4B re-
aggregated to compare expression levels between all melanomas
versus nevi and other cancers (bladder, prostate, and breast). Table 1,
A and B, summarizes the Welch t test results from all possible pair-
wise comparisons between the different tissue types displayed in the
box plots in Figure 4. Mean fold expression difference between all
melanomas and all other cancers was statistically significant at 3.405
(P value = .002182; see Figure 4C , and Table 1). These data suggest
that a subset of melanomas overexpresses ETV1 and amplification
Figure 4. Reverse Transcription–PCR of ETV1 in melanoma. ETV1-specific real-time Q-PCR was performed on melanoma tumors includ-
ing the six cases positive for ETV1 amplification. (A) ETV1-specific primers spanning the exon boundary between exons 5 and 6 (88-bp
amplicon, depicted with red arrows) were designed. (B) Relative quantification was performed using the ΔΔCT method; y-axis for both
graphs are plotted on a log-based 2 scale. For each tumor type, the box plots show a central rectangle indicating the first to third
quartiles with a horizontal line within the box corresponding to the median; the whiskers indicate the minimum and maximum, and
individual tumor samples are represented by dots in the background. The amplified melanomas include the two ETV1-specific amplified
melanomas (clear dots) and the four chromosome 7–amplified melanomas (black dots). Nevi box plot includes two dysplastic nevi (clear
dots) and seven benign nevi (black dots). There was no statistically significant mean expression difference between amplified mela-
nomas and non-amplified melanomas (Welch t test: t = 0.482, P value = .6478). (C) Raw data plotted in B aggregated to compare
ETV1 expression in all melanomas versus nevi and other cancers (bladder, prostate, and breast). There was no statistically significant
expression difference between melanomas and nevi (Welch t test: t = −0.2781, P value = .7832). Mean fold expression difference
between all melanomas versus all other cancers was 3.4051 (P value = .002182).
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of ETV1 may be the underlying mechanism for achieving high
gene expression.
In vitro and in vivo experiments indicate an important role for
ETV1 in prostate cancer oncogenesis [15]. Benign cancer cells in-
duced to express high levels of ETV1 show increased metastatic poten-
tial as assessed by a modified basement membrane invasion assay;
furthermore, these cells upregulate a gene expression signature involv-
ing cell invasion. In addition, a subset of Ewing sarcomas display an
oncogenic fusion resulting in constitutively activated ETV1 [18], and
HER2/neu-positive breast cancers express high levels of ETV1 that
contributes to tumorigenicity [19,20]. These studies, along with our
results, suggest that elevated levels of ETV1 in melanocytes may con-
tribute toward transformation to melanoma.
Our results are in accordance with the findings of a related previ-
ously published study that has reported ETV1 amplification in a sub-
set of melanomas [16]. Melanoma cell lines in this study, including
those with ETV1 amplification, exhibited dependency on ETV1 ex-
pression for proliferation and anchorage-independent growth. More-
over, overexpression of ETV1 in combination with oncogenic
NRASG12D transformed primary melanocytes and promoted tumor
formation in mice. The observations in this study implicate deregu-
lated ETV1 in melanoma genesis and suggest a pivotal lineage depen-
dency mediated by oncogenic ETS transcription factors in this
malignancy. The mechanism by which ETV1 may contribute to
melanoma formation could be the reported up-regulation of the
microphthalmia-associated transcription factor. ETV1 FISH assay
performed by these authors also exhibited a “break-apart” pattern in
two cases of metastatic melanoma, suggestive of targeted gene disrup-
tion or possible translocation of the ETV1 locus. However, we did not
find evidence of any such aberrations in any of the melanoma cases
represented on our two TMAs in the current study.
Our data reveal that nevi and melanomas have comparable expres-
sion levels of ETV1 and both show statistically significant increased
expression compared to other cancers (breast, prostate, and bladder;
see Table 1B). This would indicate that elevated ETV1 expression
would not be sufficient for malignant transformation in melanoma
because benign nevi express equivalent levels to melanomas; how-
ever, up-regulation of ETV1 could provide an early proliferative sig-
nal to melanocytes that is kept in check within nevi by an unknown
mechanism. A precedent for such a scenario is provided by the most
common genetic mutation found in melanomas, the BRAFV600E
mutation. This missense mutation is one of the most well-studied
mutations in melanomas and has been found to confer a malignant
phenotype when induced in melanocytes [21]. However, similar to
ETV1, it is expressed in both melanomas and benign nevi. Studies
using primary melanocyte cultures artificially expressing the onco-
genic BRAFV600E mutation found that these cells undergo an initial
burst of proliferation and then proceed to cell cycle arrest; this study
also showed that the melanocytes of nevi are in senescence [22].
Further studies have revealed that in established murine BRAFV600E-
driven nevi, acute shRNA-mediated depletion of PTEN prompted
tumor progression [23]. Thus, an oncogenic mutation often needs a
second mutation, perhaps involving a tumor suppressor gene, to pro-
ceed to an overt malignant phenotype. Further experiments will have to
be performed to see if this is the case for ETV1 in melanoma.
ETV1 has also been implicated in the development of gastrointes-
tinal stromal tumors (GISTs), which are primarily characterized by
mutations in the KIT or PDGFRA receptor tyrosine kinase [24].
ETV1 is universally highly expressed in GISTs. It has been proposed
that GISTs arise from interstitial cells of Cajal with high levels of
endogenous ETV1 expression that, when coupled with an activating
KIT mutation, drives an oncogenic ETS transcriptional program
[25]. This differs from what we have seen in our past work on pros-
tate cancer, our current study on melanomas, and in Ewing sarcoma
or acute myeloid leukemia, where genomic translocation or amplifi-
cation drives aberrant ETS expression.
Currently, there are only a few published ETS studies in mela-
nomas and this is the first describing a comprehensive FISH screen
on melanomas using all 27 members of the ETS family. A recent
publication reported high ETV4 (also known as E1AF) expression
in melanoma cells lines that correlated with elevated expression levels
of membrane–type-1 matrix metalloproteinase, suggesting a role for
ETV4 in melanoma invasion [26]. Toralkovic et al. suggested expres-
sion of Fli-1 in malignant melanoma to be associated with biologically
more aggressive tumors [27]. Several studies have reported on ETS-1 in
melanoma with conflicting results. An early study used immunohisto-
chemistry on a relatively small panel of melanocytic lesions (10 cutane-
ous melanomas and 24 benign melanocytic lesions) and reported that
Table 1. Welch T Test of Q-PCR Data.
(A)
Amplified Melanoma Non-amplified Melanoma Nevi Breast Cancer Prostate Cancer Bladder Cancer
Amplified melanoma
Non-amplified melanoma 0.4967 (.6377)
Nevi 0.2391 (.819) −0.6293 (.5359)
Breast cancer 1.415 (.2154) 3.1629 (.0052) 3.5737 (.00496)
Prostate cancer 1.346 (.2243) 1.8994 (.1289) 2.3172 (.07144) 0.0844 (.94)
Bladder cancer 1.593 (.1716) 3.8554 (.00126) 4.1755 (.00212) 1.8286 (.09122) 0.3385 (.7663)
(B)
All Melanomas Nevi All Other Cancers
All melanomas
Nevi −0.2781 (.7832)
All other cancers 3.405 (.002182) 3.668 (.004337)
(A) Statistical analysis using Welch t test comparisons of average expression values from Figure 4B. For each box, column heading is compared to the corresponding row heading; the t test result is given
on top with P value in parentheses below. (B) Statistical analysis using Welch t test comparisons of average expression values from Figure 4C . For each box, column heading is compared to the
corresponding row heading; the t test result is given on top with P value in parenthesis below.
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the ETS-1 staining intensity correlated with malignant behavior, i.e.,
benign melanocytic lesions showed minimal staining intensity, mela-
noma in situ revealed intermediate staining, and melanomas stained
the strongest [28]. Rothhammer et al. described similar findings using
in situ hybridization on melanocytic lesions; benign melanocytic lesions
showed lowest ETS-1 expression levels and melanoma showed highest
ETS-1 expression; in addition, a melanoma cell line with baseline high
levels of ETS-1 showed diminished ability to invade in a Boyden cham-
ber assay when ETS-1 expression was abrogated using an antisense
assay [29]. Houssaye et al. found ETS-1 and ETS-2, along with their
downstream signaling pathways, to be upregulated in pigmented ocular
neoplasms in a transgenic mouse model driving SV-40 large T antigen
using a tyrosine-related protein-1 promoter [30]. In contrast to the
aforementioned three studies, Torlakovic et al. used immunohisto-
chemistry on 218 melanocytic lesions but reported no correlation be-
tween ETS-1 staining intensity and malignant behavior, disease-specific
survival, or time to treatment failure [31]. The current study identified
a genomic basis for ETV1 overexpression and our outlier analysis sug-
gests increased transcript expression of additional ETS family members
such as ETV5, ELF1, EHF, and ETS2 genes in melanomas. This ob-
servation gain enormous significance in the light of a more recent study
that describes a tumor-specific regulation of TERT gene by ETS pro-
teins because of a recurrent somatic mutation in melanoma [1]. Huang
et al. [1] recently described two independent highly recurrent somatic
mutations in human melanoma samples. These mutations occurred in
the TERT gene core promoter region in approximately 71% of mela-
noma specimens studied. The mutation creates an ETS binding motif
and increases the transcriptional activity of the TERT promoter by
two-fold to four-fold and is considered to play a role in tumorigenesis.
In summary, our data suggest that ETS gene aberrations, apart
from ETV1, do not play a predominant role in the oncogenesis of
melanomas. Our study further confirms that ETV1 is amplified in a
subset of melanomas. Results from the recent study, which identified
generation of ETS binding site in TERT promoter, now provides a
potential oncogenic mechanism for ETV1 overexpression in melano-
mas [1]. So how can this knowledge be used in cancer treatment?
Currently, it is hard to target ETV1 directly with siRNA. However,
it is possible to use/develop enzymatic inhibitors for proteins like
poly[adenosine diphosphate (ADP)-ribose] polymerase 1 (PARP1),
which has been demonstrated to bind to ETV1 and is required for
ETV1 activity [32]. Poly(ADP-ribose) polymerase inhibitors are under
active clinical investigation and the subject of several clinical trials cur-
rently and offer hope into targeted treatment for such cancers [33].
Overall, insight into the biology of such genomic alterations will allow
novel therapies to be tailored to susceptible molecular subtypes of
melanoma cases.
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